Revolution Medicines launches $1 billion at-the-market offering

"Davis Polk advised the sales agent in connection with Revolution Medicines' SEC-registered at-the-market offering of common stock for up to $1 billion. The common stock is listed on the Nasdaq Global Select Market under the symbol RVMD. Revolution Medicines is a Redwood City-based clinical-stage oncology company."

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Revolution Medicines, Inc. The offering involved the sale of shares of Revolution Medicines' common stock for up to an aggregate amount of $1 billion through an at-the-market facility. The common stock is listed on the Nasdaq Global Select Market under the symbol RVMD. Revolution Medicines, based in Redwood City, California, is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers. Davis Polk represented the sales agent with a team composed by: partners Alan F. Denenberg and Yasin Keshvargar and associates Dove Barbanel and Matthew Kenney (corporate practice), and partner David R. Bauer and associate Jordan Khorshad (intellectual property practice). Members of the Davis Polk team were based in the firm's Northern California and New York offices.

Menu

Revolution Medicines launches $1 billion at-the-market offering

Read the full story

Menu

Revolution Medicines launches $1 billion at-the-market offering

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads